- Home
- RLYB vs BOLD Comparison
RLYB vs BOLD Comparison
Compare RLYB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLYB | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 28.4M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RLYB | BOLD |
|---|---|---|
| Price | $4.71 | $1.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.8K | ★ 178.1K |
| Earning Date | 03-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $674,000.00 | N/A |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $1.76 | $0.96 |
| 52 Week High | $6.99 | $2.48 |
Technical Indicators
Market Signals| Indicator | RLYB | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 94.88 | 44.06 |
| Support Level | $0.56 | $0.96 |
| Resistance Level | $5.37 | $1.20 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.49 | -0.01 |
| Stochastic Oscillator | 89.81 | 51.26 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.